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PUBLIC HEALTH
Antimicrobial resistance is a social problem requiring
a social solution
We need to reverse our dependency on antibiotics, whether or not new ones are discovered
Richard Smith professor of health system economics and dean, Faculty of Public Health and Policy,
London School of Hygiene and Tropical Medicine
Antimicrobial resistance has reasserted itself on the national
and international agenda as a critical threat to public health and
health systems. It undermines the very foundations of modern
healthcare, from joint replacements to chemotherapy, threatens
to reverse the decline in mortality and morbidity from infectious
diseases, jeopardises animal health and welfare, and poses
potentially crippling financial effects.1 2
It is intrinsically a biological phenomenon, which has, perhaps
naturally, led to much of the discussion on tackling it being
driven from a biological, and broader scientific, perspective.
However, the conditions promoting, or militating against, the
biological mechanisms of antimicrobial resistance are deeply
social, shaped by cultural, political, and economic processes.
Such social aspects include:
• The ways farmers, vets, and regulatory systems manage
livestock production for human consumption
• How regulatory and fiscal frameworks incentivise or deter
antimicrobial development, production, and use
• How the public and healthcare professionals understand,
value, and use antimicrobials
• The context in which animals and humans interact, and
• The ways in which particular groups of people are exposed
to particular microbial infections.3
Actions to reduce and control antimicrobial resistance will
therefore involve change in social practices, but at present the
discourse and, critically, the investment of time, money, and
intellectual capital are heavily biased towards technological
solutions.
Narrow focus on drugs and tests
Chief among these is the push for development of “novel”
antimicrobials. For example, the latest report from the
Independent Review on Antimicrobial Resistance, chaired by
Jim O’Neill, emphasised the need for de-linking drugs’
profitability from sales volumes.4 5 This builds on other recent
work, such as that by the think tank on international affairs
ChathamHouse, which has outlined alternative business models
to similarly change the current financial models for encouraging
and supporting research and development in new antibiotics.6
Meanwhile, in practice, in the United States there has been an
extension to marketing exclusivity, accelerated review, and a
relaxation of requirements for approval by the Food and Drug
Administration.7Although this leniency may have increased the
development and launch of new antibiotics, there is worrying
evidence that such “fast tracking” may generate considerable
adverse effects.8Critical, of course, is the basic fact that because
resistance to an antimicrobial begins as soon as it is developed,
new agents can never be the sole solution—and certainly not
necessarily the most cost effective or sustainable.
Mechanisms to promote the sustainable use of antimicrobials
are also needed, but work has increasingly focused on rapid
diagnostic tests to support the more “appropriate use” of
antimicrobials. This was a key topic in the previous report from
O’Neill’s review.9 Research Councils UK is also supporting
diagnostics development,10 and the influential Longitude Prize
(https://longitudeprize.org) is to be awarded to whoever first
develops a specific rapid diagnostic tool. But even if such tests
are developed they can only ever be a partial solution, and their
value will be negated by systemic factors, such as out-of-pocket
payments increasing the risk of a course of antimicrobials not
being completed, and relative costs making it more likely that
antimicrobials would be used without the test, as antimicrobials
are often very cheap. These and other factors all point to
sustainable antimicrobial use requiring considerable behavioural,
cultural, political, and economic change rather than just use of
a diagnostic test to identify whether an infection is viral or
bacterial or whether it is a sensitive or resistant infection.
New vision needed
This is not to suggest that social aspects are being ignored.
However, trends in activity, in the balance of funding between
basic and social science, and in political and popular opinion
indicate that the vision for tackling antimicrobial resistance is
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focused on technological and biomedical solutions. This is
deeply concerning. Although the mechanism for antimicrobial
resistance is biological, the problem is fundamentally social: a
problem of use and abuse and of modern health systems that
depend heavily on antibiotics. As a social problem it demands
a social solution, one based on greater understanding,
measurement, modelling, and ultimately (re)shaping the social,
political, and economic environment in which resistance
develops and antibiotics are used. But this won’t happen without
a new vision for tackling antimicrobial resistance, backed by
investment of time, money, and energy in the necessary social
science research.
The latest report from the O’Neill review recommends a global
innovation fund of around $2bn (£1.3bn; €1.8bn) to boost “blue
sky” research into drugs and diagnostics and says that a
comprehensive package of interventions in this area could cost
“as little as $16bn.”5 That may be true, but even with those
investments there is a risk that nothing will result. And any
results we do get may only be buying time.
It would be more sustainable and effective to use such funds to
support work to restructure our health systems and reverse our
dependency on antibiotics, which ultimately we will need to do
whether or not new antibiotics are discovered.
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